The increase in price target by Piper Sandler, while maintaining a Neutral rating, indicates a slight improvement in the firm's outlook on Elanco Animal Health. This adjustment could lead to a modest positive reaction in the short term as investors may view the raised target as a sign of potential growth or stability, despite the neutral stance.